177Lutetium-DOTA-octreotate therapy in progressive somatostatin receptor-expressing neuroendocrine neoplasms

被引：0
|
作者：
Delpassand, E. [1 ]
Mohammadali, H. [1 ]
Thamake, S. [2 ]
Broline, S. [1 ]
Ranganathan, D. [3 ]
Wagh, N. [3 ]
Tworowska, I. [2 ]
Delpassand, A. [2 ]
Puentes, J. [2 ]
机构：
[1] Excel Diagnost & Nucl Oncol Ctr, Houston, TX USA
[2] RadioMedix Inc, Houston, TX USA
[3] Radioisotope Therapy Amer RITA Fdn, Houston, TX USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
17
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
    W. A. van der Zwan
    T. Brabander
    B. L. R. Kam
    J. J. M. Teunissen
    R. A. Feelders
    J. Hofland
    E. P. Krenning
    W. W. de Herder
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 704 - 717
  • [32] Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
    van der Zwan, W. A.
    Brabander, T.
    Kam, B. L. R.
    Teunissen, J. J. M.
    Feelders, R. A.
    Hofland, J.
    Krenning, E. P.
    de Herder, W. W.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) : 704 - 717
  • [33] Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors: Preliminary results
    Kwekkeboom, DJ
    Kam, BL
    Bakker, WH
    Kooij, R
    Srinivasan, A
    Erion, JL
    Bugaj, JL
    Schmidt, MA
    de Jong, M
    Krenning, EP
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 1027 - 1027
  • [34] Peptide receptor radionuclide therapy of neuroendocrine neoplasms using lutetium-177 and yttrium-90 labeled somatostatin analogs: A single center experience in over 1000 patients
    Singh, A.
    Kulkarni, H. R.
    Langbein, T.
    Lehmann, C.
    Niepsch, K.
    Mueller, D.
    Hommann, M.
    Kaemmerer, D.
    Jochems, A.
    Lambin, P.
    Hoersch, D.
    Baum, R. P.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [35] Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)
    Kong, G.
    Callahan, J.
    Hofman, M.
    Pattison, D.
    Akhurst, T.
    Michael, M.
    Eu, P.
    Hicks, R.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 : 93 - 93
  • [36] [DOTA, TYR3]octreotate, labeled with 177LU, is most promising for radionuclide therapy of somatostatin receptor-positive tumors.
    De Jong, M
    Breeman, WA
    Bernard, HF
    Bakker, WH
    Srinivasan, A
    Erion, J
    Bugaj, JE
    Krenning, EP
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 111P - 111P
  • [37] Promising Results After Radionuclide Therapy With 177Lu-DOTA-octreotate in Patients With Disseminated Neuroendocrine Hindgut Tumours
    Garske, U.
    Sandstrom, M.
    Johansson, S.
    Hellman, P.
    Sundin, A.
    Eriksson, B.
    Granberg, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S422
  • [38] 177 Lu-Dota-octreotate therapy in advanced Gastrointestinal Neuroendocrine tumors: outcomes after 5 years follow
    Sansovini, M.
    Grassi, I.
    Severi, S.
    Ianniello, A.
    Nicolini, S.
    Celli, M.
    Amadori, E.
    Di Iorio, V.
    Monti, M.
    Scarpi, E.
    Bongiovanni, A.
    Lambertini, A.
    Grana, C.
    Paganelli, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S156 - S156
  • [39] Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours
    Yordanova, A.
    Wicharz, M.
    Gonzalez-Carmona, M.
    Strassburg, C.
    Mayer, K.
    Brossart, P.
    Essler, M.
    Ahmadzadehfar, H.
    [J]. NEUROENDOCRINOLOGY, 2017, 105 : 258 - 258
  • [40] Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides
    Hoersch, D.
    Prasad, V.
    Baum, R. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345